Longitudinal trajectories in renal function before and after heart failure hospitalization among patients with heart failure with preserved ejection fraction in the PARAGON-HF trial.


Journal

European journal of heart failure
ISSN: 1879-0844
Titre abrégé: Eur J Heart Fail
Pays: England
ID NLM: 100887595

Informations de publication

Date de publication:
10 2022
Historique:
revised: 11 07 2022
received: 30 04 2022
accepted: 18 07 2022
pubmed: 28 7 2022
medline: 29 11 2022
entrez: 27 7 2022
Statut: ppublish

Résumé

Worsening renal function may impact long-term outcomes in heart failure (HF). However, little is known about the longitudinal trajectories in renal function in relation to HF hospitalization or how this high-risk clinical event impacts renal outcomes. In PARAGON-HF, we evaluated the association between recency of prior HF hospitalization (occurring pre-randomization) and subsequent first renal composite outcome: (i) time to ≥50% decline in estimated glomerular filtration rate (eGFR); (ii) development of end-stage renal disease; or (iii) death attributable to renal causes. A total of 2306 (48.1%) patients had a history of prior HF hospitalization. Incident rates of the renal outcome were highest in those most recently hospitalized and decreased with longer time from last hospitalization. Treatment effect on the renal outcome of sacubitril/valsartan versus valsartan was similar between patients with (hazard ratio [HR] 0.43; 95% confidence interval [CI] 0.24-0.76) and without (HR 0.63; 95% CI: 0.33-1.18; p Heart failure hospitalization denotes increased risk for kidney disease progression which continues following recovery from HF decompensation in patients with HF with preserved ejection fraction. PARAGON-HF (Prospective Comparison of ARNI with ARB Global Outcomes in HF with Preserved Ejection Fraction), ClinicalTrials.gov NCT01920711.

Identifiants

pubmed: 35895867
doi: 10.1002/ejhf.2638
pmc: PMC10086974
doi:

Substances chimiques

sacubitril 17ERJ0MKGI
Angiotensin Receptor Antagonists 0
Tetrazoles 0
Angiotensin-Converting Enzyme Inhibitors 0
Aminobutyrates 0
Valsartan 80M03YXJ7I
Biphenyl Compounds 0
Drug Combinations 0

Banques de données

ClinicalTrials.gov
['NCT01920711']

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1906-1914

Commentaires et corrections

Type : CommentIn

Informations de copyright

© 2022 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.

Références

Eur J Heart Fail. 2022 Apr;24(4):653-656
pubmed: 35218135
J Am Heart Assoc. 2018 Aug 7;7(15):e008789
pubmed: 30371240
N Engl J Med. 2014 Apr 10;370(15):1383-92
pubmed: 24716680
J Am Coll Cardiol. 2021 Jul 27;78(4):330-343
pubmed: 33989713
Circ Heart Fail. 2014 Nov;7(6):895-902
pubmed: 25326006
Nat Rev Cardiol. 2015 Apr;12(4):220-9
pubmed: 25666406
JAMA Cardiol. 2021 Jan 1;6(1):68-77
pubmed: 33206129
Circulation. 2007 Sep 25;116(13):1482-7
pubmed: 17724259
JACC Heart Fail. 2017 Jul;5(7):471-482
pubmed: 28662936
Eur Heart J. 2014 Feb;35(7):455-69
pubmed: 24164864
Circulation. 2020 Sep 29;142(13):1236-1245
pubmed: 32845715
N Engl J Med. 2019 Oct 24;381(17):1609-1620
pubmed: 31475794
N Engl J Med. 2021 Oct 14;385(16):1451-1461
pubmed: 34449189
J Am Coll Cardiol. 2020 Jan 28;75(3):245-254
pubmed: 31726194
Arch Intern Med. 2008 Feb 11;168(3):316-24
pubmed: 18268174
Eur J Heart Fail. 2020 Apr;22(4):584-603
pubmed: 31908120
J Am Coll Cardiol. 2018 Jul 24;72(4):351-366
pubmed: 30025570
Circulation. 2020 Jul 21;142(3):230-243
pubmed: 32486833

Auteurs

Safia Chatur (S)

Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

Muthiah Vaduganathan (M)

Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

Alexander Peikert (A)

Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

Brian L Claggett (BL)

Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

Finnian R McCausland (FR)

Renal Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

Hicham Skali (H)

Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

Marc A Pfeffer (MA)

Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

Iris E Beldhuis (IE)

University of Groningen, Department of Cardiology, University Medical Center Groningen, Groningen, The Netherlands.

Lars Kober (L)

Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark.

Petar Seferovic (P)

University of Belgrade School of Medicine, Belgrade University Medical Center, Belgrade, Serbia.

Martin Lefkowitz (M)

Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.

John J V McMurray (JJV)

BHF Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.

Scott D Solomon (SD)

Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH